Efficacy And Safety Of Chimeric Antigen Receptor T Cell Immunotherapy In B-Cell Non-Hodgkin Lymphoma: A Systematic Review And Meta-Analysis

Aim: The aim was to evaluate the efficacy and safety of chimeric antigen receptor T (CAR-T) cell in B-cell non-Hodgkin lymphoma (B-NHL). Materials & methods: A meta-analysis was conducted using eligible clinical trials, which were obtained from electronic medical literature databases. Results: A total of 24 clinical trials with 590 patients were included. The best overall response rate was 66% and complete remission rate was 46%. The incidence rates of cytokine-release syndrome and neurotoxicity (grade >= 3) were 9 and 5%, respectively. The various clinical factors were analyzed. Autogenic CAR-T cell may lead to improved efficacy than allogeneic CAR-T cell. CD20 CAR-T cell may show increased efficacy than CD19 CAR-T cell. Conclusion: CAR-T immunotherapy has remarkable efficacy and low toxicity in relapsed/refractory B-NHL.Lay abstractImmunotherapy has demonstrated remarkable antitumor activity in the field of lymphoma (a type of blood cancer that develops when white blood cells grow out of control) compared with conventional treatment methods. Simultaneously, the toxicity associated with immunotherapy is attracting the attention of researchers. We conducted a study to further reveal the effectiveness and safety of an emerging immunotherapy method to treat lymphoma. We analyze several clinical factors that may affect the outcome of treatment, hoping to provide useful information with regards to the treatment of lymphoma. Our results indicated that this emerging immunotherapy method has remarkable efficacy and low toxicity in lymphoma.